LianBio

0.0700+0.00 (+0%)

Oct 29, 4:00:00 PM EDT · OTC Markets OTCPK · LIANY · USD

Upcoming Earnings

Report date

≈ -

Key Stats

Market Cap

7.64M

P/E (TTM)

Basic EPS (TTM)

-0.82

Dividend Yield

Recent Filings

8-K

LianBio initiates wind down, dividend

2/13/24Feb 13, 2024

LianBio's board, after a thorough strategic review, greenlit a full wind down of operations on February 13, 2024, kicking off asset sales, a 50% workforce cut in Q1, and Nasdaq delisting by March 18. They declared a $4.80 per share special dividend, totaling ~$528 million, payable March 11 to ordinary shareholders and March 14 to ADS holders. Wind down wraps substantially by year-end 2024, dissolution by mid-2027. No recovery of original investments is assured.

8-K

LianBio sells NBTXR3 rights

12/26/23Dec 26, 2023

LianBio sold its rights to develop and commercialize NBTXR3, an investigational radioenhancer, in key Asian markets to Janssen for a $25 million upfront payment, effective December 22, 2023. The deal includes a potential $5 million sales milestone if net sales in China top $20 million in a year. Transition wraps up in six months. Cash bolsters LianBio's position amid portfolio shifts.

8-K

CFO resigns, interim appointed

12/20/23Dec 20, 2023

LianBio's CFO Yi Larson resigned effective December 19, 2023, to chase new opportunities, triggering a $2.4 million severance package paid in installments. The board swiftly named Ehong Gu, its VP of Global Finance, as interim CFO that day, leveraging her decade-plus in biotech finance. Smooth transition. No compensation details for Gu yet, but an indemnification agreement is in place.

8-K

CEO resigns; interim appointed

12/19/23Dec 19, 2023

LianBio's CEO Yizhe Wang resigned effective December 16, 2023, to pursue other opportunities, securing a $1,525,000 severance over one year plus accelerated equity vesting. Board member Adam Stone stepped in as interim CEO that day, drawing on his Perceptive Advisors experience without added pay. The board eyes strategic alternatives, with updates due in Q1 2024. Leadership shift tests continuity amid ongoing review.

8-K

LianBio rejects undervalued bid

12/6/23Dec 6, 2023

LianBio's Board unanimously rejected an unsolicited acquisition proposal from Concentra Biosciences on December 6, 2023, deeming the $4.30 per share cash offer plus 80% contingent value right from program dispositions undervalued. The decision prioritizes shareholder interests amid the company's focus on advancing oncology, ophthalmology, and inflammatory disease candidates in Asian markets. Yet the board stands firm.

About

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.

CEO

Mr. Konstantin Poukalov

IPO

11/1/2021

Website

https://www.lianbio.com

Employees

163

Sector

Healthcare

Industry

Biotechnology